Nwr Communications

Nwr Communications company information, Employees & Contact Information

NWR Communications is an investor and media relations firm with offices in Melbourne, Sydney and Perth. We work with a range of small-to-mid cap ASX-listed companies. We work with clients to build awareness and relationships within the investment community and media.

Company Details

Employees
50
Founded
-
Address
350 Collins Street, Level 6,australia
Phone
+61 420 582 887
Email
ti****@****.com.au
Industry
Public Relations And Communications Services
NAICS
Public Relations Agencies
HQ
Melbourne , VIC
Looking for a particular Nwr Communications employee's phone or email?

Nwr Communications Questions

News

Financial Results Webinar - GlobeNewswire

Financial Results Webinar GlobeNewswire

Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors - Investing News Network

Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors Investing News Network

Perseus Mining Quarterly Report Investor Webinar - GlobeNewswire

Perseus Mining Quarterly Report Investor Webinar GlobeNewswire

McLaren Minerals – Drilling Commenced at McLaren Titanium Project, WA - GOLDINVEST.de

McLaren Minerals – Drilling Commenced at McLaren Titanium Project, WA GOLDINVEST.de

Everest Metals Greenstone Belts Update Highlights Gold and Critical Minerals - Discovery Alert

Everest Metals Greenstone Belts Update Highlights Gold and Critical Minerals Discovery Alert

Appointment of Managing Director and Chief Executive Officer - GlobeNewswire

Appointment of Managing Director and Chief Executive Officer GlobeNewswire

Five-Year Gold Production Outlook Webinar - GlobeNewswire

Five-Year Gold Production Outlook Webinar GlobeNewswire

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee - Investing News Network

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee Investing News Network

Webinar notification – IKE’s quarterly performance update - BusinessDesk

Webinar notification – IKE’s quarterly performance update BusinessDesk

Aroa Biosurgery Launches New Product, Myriad Morcells™ - Offering Highly Conformable Tissue Regeneration in Wound Beds - Following Recent FDA Clearance - Business Wire

Aroa Biosurgery Launches New Product, Myriad Morcells™ - Offering Highly Conformable Tissue Regeneration in Wound Beds - Following Recent FDA Clearance Business Wire

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases - Investing News Network

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases Investing News Network

Change to Perseus's Senior Management Team - GlobeNewswire

Change to Perseus's Senior Management Team GlobeNewswire

Vonex : to present at virtual conference, Friday 27 March - MarketScreener

Vonex : to present at virtual conference, Friday 27 March MarketScreener

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart - Investing News Network

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart Investing News Network

Nyanzaga Gold Project Technical Report - GlobeNewswire

Nyanzaga Gold Project Technical Report GlobeNewswire

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177 - Investing News Network

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177 Investing News Network

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake - Investing News Network

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake Investing News Network

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia - Investing News Network

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia Investing News Network

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia - GlobeNewswire

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia GlobeNewswire

Investor Webinar – 3pm AEST Tuesday 2 July - Investing News Network

Investor Webinar – 3pm AEST Tuesday 2 July Investing News Network

Top Nwr Communications Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant